SWOG S1400F (NCT03373760): A phase II study of durvalumab plus tremelimumab for previously treated patients with acquired resistance to PD-1 checkpoint inhibitor therapy and stage IV squamous cell lung cancer (Lung-MAP Sub-study).
Leighl, NB; Redman, MW; Rizvi, NA; Hirsch, FR; Mack, PC; Schwartz, LH; Wade, JL; Irvin, WJ; Reddy, S; Crawford, J; Bradley, JD; Stinchcombe, T; Ramalingam, SS; Miao, J; Minichiello, K; Gandara, DR; Herbst, RS; Papadimitrakopoulou, V; Kelly, K
Volume / Issue
Electronic International Standard Serial Number (EISSN)
International Standard Serial Number (ISSN)